Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,219 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inflammatory Bowel Diseases (IBD) Clear all
Completed No phase listed Observational Accepts healthy volunteers

The Healthy Endoscopy Study

NCT04369963
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Functional Gastrointestinal Disorders
Interventions
Esophagogastroduodenoscopy and Colonoscopy with Biopsies
Procedure
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
18 Years to 25 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 18, 2026, 9:08 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

NCT06598943
View directory record Official record
Conditions
Ulcerative Colitis, Ulcerative Colitis Chronic
Interventions
Eltrekibart, Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Chandler, Arizona • Little Rock, Arkansas • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 18, 2026, 9:08 AM EDT
Completed Not applicable Interventional Results available

Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions

NCT03938324
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
Interventions
PiCASO Intervention Group, Sham Comparator: Attention Control Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 22 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 18, 2026, 9:08 AM EDT
Not listed Phase 3 Interventional

A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

NCT05181137
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SHR0302, Placebo
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
23
States / cities
Dothan, Alabama • Lancaster, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 18, 2026, 9:08 AM EDT
Recruiting No phase listed Observational

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease

NCT00904878
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2028
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 18, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

NCT02065570
View directory record Official record
Conditions
Crohn's Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 18, 2026, 9:08 AM EDT
Not listed Phase 1Phase 2 Interventional

Beta-Hydroxybutyrate Feasibility Treating IBD

NCT06351124
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Diseases
Interventions
Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's
Biological
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 18, 2026, 9:08 AM EDT
Completed No phase listed Observational Results available

Imaging Biomarkers in Crohn's Associated Spondyloarthritis

NCT02709694
View directory record Official record
Conditions
Crohn's Disease, Spondyloarthritis
Interventions
No intervention
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 18, 2026, 9:08 AM EDT
Completed Not applicable Interventional

Diet Study on Ulcerative Colitis

NCT04147598
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
LFD, SAD
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 18, 2026, 9:08 AM EDT
Terminated Phase 2 Interventional Results available

The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents

NCT00899678
View directory record Official record
Conditions
Crohn's Disease
Interventions
Certolizumab Pegol
Drug
Lead sponsor
UCB Celltech
Industry
Eligibility
6 Years to 17 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
24
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 18, 2026, 9:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of an 8-day Advanced Meditation, Samyama on Physical, Psychological and Spiritual Wellbeing ,and Associated Neural Mechanisms

NCT04366544
View directory record Official record
Conditions
Mental Health Wellness 1, Happiness, Depression, Consciousness, Level Altered, Ecstasy, Dietary Habits, Stress, Inflammatory Bowel Diseases
Interventions
Part A1: Survey, Part A2: Sample collection, Part B:
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 18, 2026, 9:08 AM EDT
Terminated Phase 3 Interventional Results available

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

NCT01190839
View directory record Official record
Conditions
Crohn's Disease
Interventions
Infliximab, Placebo
Biological · Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
62
States / cities
Birmingham, Alabama • La Jolla, California • Orange, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 18, 2026, 9:08 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Feasibility of ActivSightTM in Human

NCT04633512
View directory record Official record
Conditions
Acute Cholecystitis, Colorectal Cancer, Diverticulitis, Colonic, Obesity, Morbid, Inflammatory Bowel Diseases
Interventions
ActivSight
Device
Lead sponsor
Activ Surgical
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Houston, Texas • Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 18, 2026, 9:08 AM EDT
Not listed No phase listed Observational

The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States

NCT03952364
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, IBD, Inflammatory Bowel Diseases
Interventions
PredictSURE IBD™
Other
Lead sponsor
PredictImmune Ltd
Industry
Eligibility
16 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Miami, Florida • St Louis, Missouri • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 18, 2026, 9:08 AM EDT
Recruiting Phase 3 Interventional

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

NCT06651281
View directory record Official record
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
Tulisokibart, Placebo to tulisokibart
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Not listed
Enrollment
1,380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
12
States / cities
Bristol, Connecticut • Ypsilanti, Michigan • Liberty, Missouri + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 18, 2026, 9:08 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis

NCT04548583
View directory record Official record
Conditions
Crohn Colitis
Interventions
Remestemcel-L, Placebo
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 18, 2026, 9:08 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 18, 2026, 9:08 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

NCT06699121
View directory record Official record
Conditions
Primary Sclerosing Cholangitis (PSC)
Interventions
LB-P8 low-dose, LB-P8 high-dose, Placebo
Drug
Lead sponsor
LISCure Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 18, 2026, 9:08 AM EDT
Terminated Not applicable Interventional Results available

An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery

NCT01002287
View directory record Official record
Conditions
Ulcerative Colitis, Familial Polyposis
Interventions
SprayShield Adhesion Barrier System, Good Surgical Technique Alone
Device · Procedure
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Oct 18, 2026, 9:08 AM EDT
Terminated Not applicable Interventional

Study of Dietary Composition in Crohn's Disease

NCT04431700
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease
Interventions
Anti-inflammatory diet, Regular diet
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 18, 2026, 9:08 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

NCT03464136
View directory record Official record
Conditions
Crohn Disease
Interventions
Placebo for Ustekinumab, Placebo for Adalimumab, Ustekinumab (6 mg/kg), Ustekinumab (90 mg), Adalimumab (40 mg)
Biological
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
67
States / cities
Mobile, Alabama • San Diego, California • Colorado Springs, Colorado + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 18, 2026, 9:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glucocorticoid-induced Osteopenia in Children

NCT00289328
View directory record Official record
Conditions
Crohn's Disease, Nephrotic Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years to 21 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 18, 2026, 9:08 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Urine Metabolites in the Diagnosis of Disease

NCT06710067
View directory record Official record
Conditions
Colorectal Cancer, Small Intestinal Bacterial Overgrowth Syndrome (SIBO), Crohn Disease, Celiac Disease
Interventions
Not listed
Lead sponsor
Luventix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Encinitas, California • Santa Monica, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 18, 2026, 9:08 AM EDT
Withdrawn Phase 3 Interventional

SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery

NCT05104229
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Venous Thromboembolism
Interventions
Aspirin 81Mg Ec Tab, Standard of Care
Drug
Lead sponsor
Stefan Holubar MD MS FACS, FASCRS
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 18, 2026, 9:08 AM EDT